← All trials
NCT04639986
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2020
- Primary completion
- Dec 14, 2022
- Completion date
- Dec 31, 2023
- First posted
- Nov 23, 2020
- Last posted
- Nov 25, 2020
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Everest MedicinesLead sponsor
- ParexelCollaborator
- Medidata SolutionsCollaborator
- IQVIACollaborator
- Everest MedicinesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.